Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Everett E. Vokes to Immunotherapy

This is a "connection" page, showing publications Everett E. Vokes has written about Immunotherapy.

 
Connection Strength
 
 
 
0.907
 
  1. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207.
    View in: PubMed
    Score: 0.427
  2. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.151
  3. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.143
  4. Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clin Lung Cancer. 2018 09; 19(5):377-386.
    View in: PubMed
    Score: 0.118
  5. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.036
  6. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.